Piper Jaffray analyst Danielle Brill says FDA approval of Sage Therapeutics' Zulresso for postpartum depression, product labeling, and gross pricing of $34,000 are "entirely in-line with expectations." The analyst continues to believe the opportunity of a 60-hour intravenous infusion with restricted use is modest at $300M in peak sales. However, the commercial footprint Sage can establish with Zulresso should position the company well for maximal success with SAGE-217 in the postpartum depression setting, Brill tells investors in a research note. She reiterates an Overweight rating on the shares with a $206 price target.